Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
MWN-AI** Summary
Agios Pharmaceuticals, Inc. reported its fourth-quarter and full-year financial results for 2025, highlighting significant milestones and developments in its product pipeline. PYRUKYND® (mitapivat) generated worldwide net revenues of $20 million in Q4 and $54 million for the entire year. The fourth quarter alone saw U.S. net revenue from PYRUKYND reach $16 million, marking a 49% increase compared to Q4 2024.
A pivotal development for Agios was the FDA approval of AQVESME™ (mitapivat) as the first treatment for adults with anemia due to non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. This product is expected to significantly enhance Agios’s market presence, with a strong launch anticipated in 2026. Additionally, the company announced plans for a pre-supplemental New Drug Application (sNDA) meeting with the FDA regarding mitapivat’s application in treating sickle cell disease, with expectations to submit a marketing application afterward.
In terms of clinical advancements, Agios has fully enrolled its Phase 2 trial for tebapivat in sickle cell disease, with topline results expected in the latter half of 2026. Financially, as of December 31, 2025, Agios held $1.2 billion in cash, cash equivalents, and marketable securities, providing a strong foundation for executing its commercial strategies and advancing clinical programs.
Despite a net loss of $108 million in Q4 2025, up from a loss of $96.5 million in Q4 2024, Agios remains committed to achieving significant growth in the rare disease sector. The company views 2026 as a critical year for expanding its portfolio and delivering transformative therapies to patients.
MWN-AI** Analysis
Agios Pharmaceuticals recently reported its Q4 and full-year financial results for 2025, revealing notable developments and challenges that offer insights for potential investors. The company generated $20 million in net revenues during Q4 and $54 million for the entire year, primarily from its therapies PYRUKYND® and the newly launched AQVESME™ for thalassemia. With the FDA’s approval of AQVESME in December 2025, Agios is positioned for significant growth, particularly with the U.S. launch underway.
Investor sentiment should be cautious yet optimistic. The company's cash and equivalents stand at approximately $1.2 billion, providing a robust buffer for operational expenses and development initiatives, particularly as the company gears up for a pre-sNDA meeting with the FDA regarding mitapivat for sickle cell disease. This engagement is crucial as it may set the stage for additional revenue streams if approved.
Looking ahead, topline results from the Phase 2 trial of tebapivat in sickle cell disease are anticipated in late 2026. Agios is pursuing a diligent approach to capital allocation, aiming to expand both its commercial footprint and pipeline diversity, which may attract investor interest.
However, the increasing net loss of $108 million in Q4 compared to $96.5 million the previous year indicates that while growth prospects are promising, significant expenditures in R&D could continue to pressure profitability in the near term.
For investors, a strategy of gradual entry into AGIO may be prudent, monitoring the upcoming regulatory interactions and trial results closely. Given the company’s strong foundation and potential for breakthrough therapies in hematologic conditions, AGIO could represent a compelling opportunity for those willing to endure volatility in pursuit of long-term gains.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- PYRUKYND® (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full year
- AQVESME™ (mitapivat) for thalassemia now available in U.S. following FDA approval
- Company will have pre-sNDA meeting with FDA for mitapivat in sickle cell disease in first quarter of 2026
- Phase 2 tebapivat trial in sickle cell disease fully enrolled; topline results expected in second half of 2026
- $1.2 billion dollars in cash, cash equivalents, and marketable securities as of December 31, 2025
CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and updates for the fourth quarter and year ended December 31, 2025.
“2025 was another year of continued execution across our portfolio, highlighted by the historic U.S. approval of AQVESME – the only medicine approved to treat anemia in adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. The U.S. launch is off to a strong start, with AQVESME now available and earning an enthusiastic response from the thalassemia community,” said Brian Goff, Chief Executive Officer, Agios. “In 2026, we are focused on driving a high-impact U.S. launch of AQVESME, expanding our PK activation franchise into additional high-value indications such as sickle cell disease and lower-risk myelodysplastic syndromes, and advancing our promising early-stage pipeline to further diversify across hematologic and other rare diseases. With disciplined capital allocation and strong operational execution, we are very well positioned at this critical inflection point to deliver a transformative medicine for the thalassemia community and advance our clinical programs as we work toward our goal of becoming a sustainable rare disease company.”
Fourth Quarter 2025 and Recent Corporate Highlights
Mitapivat Commercial Performance and Update
- PYRUKYND® (mitapivat 5 mg, 20 mg, 50 mg)
- $16.0 million in U.S. net revenue in the fourth quarter of 2025, driven by continued commercial focus in pyruvate kinase (PK) deficiency ahead of the U.S. commercial launch of AQVESME™ (mitapivat) in thalassemia, an additional ordering week in the fourth quarter, and favorable gross-to-net adjustments. This represents an increase of 49 percent from $10.7 million in the fourth quarter of 2024 and a 24 percent increase from $12.9 million in the third quarter of 2025.
- $4.0 million in ex-U.S. net revenue in the fourth quarter of 2025, driven by inventory stocking ahead of demand pull-through in Europe for PK deficiency, as patients transition onto commercial supply.
- AQVESME™ (mitapivat 100 mg)
- In December 2025, the U.S. Food and Drug Administration (FDA) approved AQVESME as the only medicine for the treatment of anemia in adults with alpha- or beta-thalassemia, regardless of transfusion burden.
- AQVESME is now available in the U.S. following the implementation of its Risk Evaluation and Mitigation Strategy (REMS) program in late January 2026.
R&D Highlights
- Mitapivat
- Sickle Cell Disease –
- Topline results from the RISE UP Phase 3 trial of mitapivat in sickle cell disease were reported in November 2025.
- Agios will have a pre-supplemental New Drug Application (sNDA) meeting with the FDA in the first quarter of 2026 and intends to submit a U.S. marketing application for mitapivat in sickle cell disease following that engagement. The company will provide an update on its regulatory filing strategy following receipt of the meeting minutes.
- Sickle Cell Disease –
- Tebapivat
- Sickle Cell Disease –
- Agios has completed enrollment for the Phase 2 trial of tebapivat in sickle cell disease, and expects to report topline results in the second half of 2026. This double-blind, randomized, placebo-controlled trial is evaluating three tebapivat doses (2.5 mg, 5 mg, and 7.5 mg) versus matched placebo over a 12-week period. The primary endpoint is hemoglobin response, defined as a ?1.0 g/dL increase in average hemoglobin concentration from Week 10 through Week 12 compared with baseline.
- Agios has completed enrollment for the Phase 2 trial of tebapivat in sickle cell disease, and expects to report topline results in the second half of 2026. This double-blind, randomized, placebo-controlled trial is evaluating three tebapivat doses (2.5 mg, 5 mg, and 7.5 mg) versus matched placebo over a 12-week period. The primary endpoint is hemoglobin response, defined as a ?1.0 g/dL increase in average hemoglobin concentration from Week 10 through Week 12 compared with baseline.
- Sickle Cell Disease –
Fourth Quarter 2025 Financial Results
For the quarter ended December 31, 2025, net loss was $108.0 million dollars, compared to net loss of $96.5 million dollars for the quarter ended December 31, 2024.
- Net product revenue from U.S. sales of PYRUKYND for the fourth quarter of 2025 was $16.0 million, compared to $10.7 million for the fourth quarter of 2024.
- Net product revenue from ex-U.S. sales of PYRUKYND for the fourth quarter of 2025 was $4.0 million.
- Cost of sales for the fourth quarter of 2025 was $1.9 million.
- Research and Development (R&D) Expenses were $88.1 million for the fourth quarter of 2025, compared to $82.8 million for the fourth quarter of 2024, associated with the advancement of the company’s early-stage clinical programs.
- Selling, General and Administrative (SG&A) Expenses were $51.6 million for the fourth quarter of 2025, which were flat compared to $51.7 million for the fourth quarter of 2024.
- Cash, cash equivalents and marketable securities were $1.2 billion as of December 31, 2025, compared to $1.5 billion as of December 31, 2024. Agios expects that its cash, cash equivalents and marketable securities, together with anticipated product revenue and interest income, will provide the financial independence to execute the U.S. commercial launch of AQVESME in thalassemia, prepare for the potential U.S. commercial launch of mitapivat in sickle cell disease, advance the company’s existing clinical programs, and opportunistically expand its pipeline through both internally and externally discovered assets.
Conference Call Information
Agios will host a conference call and live webcast today at 8:00 a.m. ET to discuss the company’s fourth quarter and full year 2025 financial results and recent business highlights. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be available on the company’s website approximately two hours after the event.
About Agios: Fueled by Connections to Transform Rare Diseases™
At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities – collaborating to develop and deliver innovative medicines that have the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit www.agios.com and follow us on LinkedIn and X.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential benefits of PYRUKYND® (mitapivat), AQVESME™ (mitapivat), tebapivat, AG-236 and AG-181; Agios’ plans, strategies and expectations for its preclinical, clinical and commercial advancement of its drug development, including mitapivat, tebapivat, AG-236 and AG-181; Agios’ expectations for the review of marketing applications for mitapivat by regulatory agencies, including the FDA and European Commission; Agios’ strategic vision and goals; and the potential benefits of Agios’ strategic plans and focus. The words “anticipate,” “expect,” “goal,” “hope,” “milestone,” “plan,” “potential,” “possible,” “strategy,” “will,” “vision,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios’ current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios’ product candidates will successfully continue. There can be no guarantee that any positive developments in Agios’ business will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including, without limitation: risks and uncertainties related to the impact of pandemics or other public health emergencies to Agios’ business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Agios’ results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios’ ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Agios' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios’ ability to establish and maintain key collaborations; uncertainty regarding any royalty payments related to the sale of its oncology business or any milestone or royalty payments related to its in-licensing of AG-236, and the uncertainty of the timing of any such payments; uncertainty of the results and effectiveness of the use of Agios’ cash and cash equivalents; and general economic and market conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in Agios’ public filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
| Consolidated Balance Sheet Data | |||||
| (in thousands) | |||||
| (Unaudited) | |||||
| December 31, 2025 | December 31, 2024 | ||||
| Cash, cash equivalents, and marketable securities | $ | 1,164,438 | $ | 1,532,031 | |
| Accounts receivable, net | 10,577 | 4,109 | |||
| Inventory | 32,920 | 27,616 | |||
| Total assets | 1,297,225 | 1,663,199 | |||
| Stockholders' equity | 1,193,114 | 1,540,956 |
| Consolidated Statements of Operations Data | |||||||||||
| (in thousands, except share and per share data) | |||||||||||
| (Unaudited) | |||||||||||
| Years Ended Dec 31, | |||||||||||
| 2025 | 2024 | 2023 | |||||||||
| Revenues: | |||||||||||
| Product revenue, net | $ | 54,028 | $ | 36,498 | $ | 26,823 | |||||
| Total revenue | 54,028 | 36,498 | 26,823 | ||||||||
| Operating expenses: | |||||||||||
| Cost of sales | $ | 6,345 | $ | 4,165 | $ | 2,881 | |||||
| Research and development | 339,535 | 301,286 | 295,526 | ||||||||
| Selling, general and administrative | 180,280 | 156,784 | 119,903 | ||||||||
| Total operating expenses | 526,160 | 462,235 | 418,310 | ||||||||
| Loss from operations | (472,132 | ) | (425,737 | ) | (391,487 | ) | |||||
| Gain on sale of contingent payments | — | 889,136 | — | ||||||||
| Milestone payment from gain on sale of oncology business | — | 200,000 | — | ||||||||
| Interest income, net | 56,379 | 48,083 | 33,344 | ||||||||
| Other income, net | 1,956 | 6,487 | 6,055 | ||||||||
| Net (loss) income before taxes | (413,797 | ) | 717,969 | (352,088 | ) | ||||||
| Income tax (benefit) expense | (1,016 | ) | 44,244 | — | |||||||
| Net (loss) income | $ | (412,781 | ) | $ | 673,725 | $ | (352,088 | ) | |||
| Net (loss) income per share - basic | $ | (7.12 | ) | $ | 11.86 | $ | (6.33 | ) | |||
| Net (loss) income per share - diluted | $ | (7.12 | ) | $ | 11.64 | $ | (6.33 | ) | |||
| Weighted-average number of common shares used in computing net (loss) income per share – basic | 57,972,004 | 56,807,415 | 55,651,487 | ||||||||
| Weighted-average number of common shares used in computing net (loss) income per share – diluted | 57,972,004 | 57,889,255 | 55,651,487 |
Contacts:
Investor Contact
Morgan Sanford, Vice President, Investor Relations
Agios Pharmaceuticals
morgan.sanford@agios.com
Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
eamonn.nolan@agios.com
FAQ**
What strategies does Agios Pharmaceuticals Inc. AGIO plan to implement to increase worldwide net revenues for PYRUKYND® (mitapivat) and AQVESME™ in the upcoming quarters, especially post-FDA approval for thalassemia?
How does Agios Pharmaceuticals Inc. AGIO anticipate the upcoming pre-sNDA meeting with the FDA will impact the timeline for mitapivat's potential approval in sickle cell disease?
Given the $1.2 billion in cash, how does Agios Pharmaceuticals Inc. AGIO prioritize its capital allocation to expand its innovative treatment portfolio while managing its significant net losses?
What key performance indicators will Agios Pharmaceuticals Inc. AGIO focus on to measure the success of the U.S. launch of AQVESME™ and to drive adoption within the thalassemia community?
**MWN-AI FAQ is based on asking OpenAI questions about Agios Pharmaceuticals Inc. (NASDAQ: AGIO).
NASDAQ: AGIO
AGIO Trading
3.97% G/L:
$28.005 Last:
208,618 Volume:
$27.53 Open:
